Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Options for Psoriasis Rebound Post-Efalizumab
NCT01079988Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2004
- Primary completion
- Dec 2004
- Modality
- Peptides, Orthosteric Ligands
01
Overview
A Phase 4 trial of cyclosporine, acitretin, methotrexate in psoriasis, sponsored by Merck KGaA. Started Feb 2004; status: completed.
02
Drugs
cyclosporineacitretinmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT01079988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079988.